$2.59 Earnings Per Share Expected for Teleflex Incorporated (NYSE:TFX) This Quarter

Equities research analysts predict that Teleflex Incorporated (NYSE:TFX) will report $2.59 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Teleflex’s earnings, with the lowest EPS estimate coming in at $2.54 and the highest estimate coming in at $2.66. Teleflex posted earnings per share of $2.47 during the same quarter last year, which indicates a positive year over year growth rate of 4.9%. The business is expected to issue its next earnings results on Thursday, August 1st.

On average, analysts expect that Teleflex will report full year earnings of $11.05 per share for the current financial year, with EPS estimates ranging from $11.00 to $11.25. For the next financial year, analysts anticipate that the company will post earnings of $12.79 per share, with EPS estimates ranging from $12.45 to $13.32. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Teleflex.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 2nd. The medical technology company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.17 by $0.07. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The company had revenue of $613.60 million for the quarter, compared to the consensus estimate of $608.27 million. During the same quarter in the prior year, the business earned $2.15 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis.



TFX has been the topic of several research reports. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $325.00 target price (up previously from $300.00) on shares of Teleflex in a research report on Friday, February 22nd. Barclays set a $287.00 target price on Teleflex and gave the company a “hold” rating in a research report on Friday, February 22nd. Morgan Stanley upped their target price on Teleflex from $305.00 to $315.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $338.00 target price on the stock in a research report on Friday, May 10th. Finally, Wells Fargo & Co initiated coverage on Teleflex in a research report on Tuesday. They issued an “outperform” rating and a $345.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teleflex has an average rating of “Buy” and an average price target of $330.00.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $277.14, for a total transaction of $55,428.00. Following the completion of the sale, the director now directly owns 589 shares in the company, valued at approximately $163,235.46. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Benson Smith sold 8,500 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $296.00, for a total value of $2,516,000.00. Following the sale, the director now owns 85,300 shares of the company’s stock, valued at $25,248,800. The disclosure for this sale can be found here. Insiders have sold 44,400 shares of company stock valued at $13,235,810 over the last 90 days. Corporate insiders own 2.36% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Norges Bank bought a new position in Teleflex in the 4th quarter valued at about $104,380,000. Geode Capital Management LLC lifted its position in Teleflex by 56.7% in the 1st quarter. Geode Capital Management LLC now owns 643,500 shares of the medical technology company’s stock valued at $194,100,000 after acquiring an additional 232,786 shares in the last quarter. Janus Henderson Group PLC lifted its position in Teleflex by 18.5% in the 1st quarter. Janus Henderson Group PLC now owns 962,391 shares of the medical technology company’s stock valued at $290,796,000 after acquiring an additional 150,201 shares in the last quarter. First Trust Advisors LP lifted its position in Teleflex by 247.5% in the 1st quarter. First Trust Advisors LP now owns 181,850 shares of the medical technology company’s stock valued at $54,948,000 after acquiring an additional 129,524 shares in the last quarter. Finally, Marshall Wace North America L.P. lifted its position in Teleflex by 32.2% in the 1st quarter. Marshall Wace North America L.P. now owns 494,782 shares of the medical technology company’s stock valued at $149,502,000 after acquiring an additional 120,411 shares in the last quarter. Hedge funds and other institutional investors own 91.52% of the company’s stock.

Shares of Teleflex stock traded up $6.22 on Wednesday, hitting $315.79. The stock had a trading volume of 168,876 shares, compared to its average volume of 377,562. Teleflex has a twelve month low of $226.02 and a twelve month high of $314.74. The company has a current ratio of 2.27, a quick ratio of 1.41 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $14.09 billion, a price-to-earnings ratio of 31.90, a PEG ratio of 2.05 and a beta of 0.94.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Wednesday, May 15th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Tuesday, May 14th. Teleflex’s dividend payout ratio (DPR) is currently 13.74%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Recommended Story: Trade Deficit

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.